Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Maecke

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 26, 2014
Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot studyDamian Wild, Melpomeni Fani, Richard Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Theranostics|July 23, 2016
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PETChristian Stoykow, Thalia Erbes, Helmut R Maecke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogsDik J Kwekkeboom, Jan Mueller-Brand, Giovanni Paganelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance pStefan Kneifel, Dominik Cordier, Stephan Good, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 20, 2016
The prognostic and predictive value of sstr<sub>2</sub>-immunohistochemistry and sstr<sub>2</sub>-targeted imaging in neuroendocrine tumorsPhilippe Brunner, Ann-Catherine Jörg, Katharina Glatz, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 26, 2014
Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot studyDamian Wild, Melpomeni Fani, Richard Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Theranostics|July 23, 2016
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PETChristian Stoykow, Thalia Erbes, Helmut R Maecke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogsDik J Kwekkeboom, Jan Mueller-Brand, Giovanni Paganelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance pStefan Kneifel, Dominik Cordier, Stephan Good, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 20, 2016
The prognostic and predictive value of sstr<sub>2</sub>-immunohistochemistry and sstr<sub>2</sub>-targeted imaging in neuroendocrine tumorsPhilippe Brunner, Ann-Catherine Jörg, Katharina Glatz, et al.
Pageof 9